<DOC>
	<DOCNO>NCT01109706</DOCNO>
	<brief_summary>PCSK9 ( Proprotein convertase subtilisin kexin type 9 ) play key role LDL-cholesterol ( LDLC ) metabolism inhibit LDL receptor ( LDLR ) post-transcriptional level . PCSK9 loss function mutation associate decreased LDLC level cardiovascular protection . In context , development pharmacological inhibitor PCSK9 , association statin treatment , represent major therapeutic issue LDLC modulation . It previously show PCSK9 plasmatic concentration correlate plasmatic LDLC , TG glucose concentration . However , data available predictive value PCSK9 plasmatic level concern coronary disease severity . The main objective study determine whether plasmatic PCSK9 concentration link coronary damage severity patient acute coronary syndrome .</brief_summary>
	<brief_title>Relevance Plasma PCSK9 Concentration Biomarker Acute Coronary Syndrome .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Inclusion criterion : 18 year old Acute coronary syndrome ( ST+ ST ) 2 group patient : statin , without statin treatment Exclusion criterion : Patient cancer last 5 year cancer progress Patient severe infection progress Hepatic failure ( TP &lt; 50 % ) Severe kidney failure Patient unable give consent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>PCSK9</keyword>
	<keyword>cardiovascular safety</keyword>
</DOC>